Haemodialysis using high cut-off dialysers for treating acute renal failure in multiple myeloma
- PMID: 22294003
- DOI: 10.3265/Nefrologia.pre2011.Nov.11094
Haemodialysis using high cut-off dialysers for treating acute renal failure in multiple myeloma
Abstract
Introduction: Acute renal failure (ARF) occurs in 12%-20% of all multiple myeloma (MM) cases, and the survival of these patients depends on renal function recovery. Renal function is not recovered in 75% of dialysis-dependent patients, and their mean survival with replacement therapy is less than one year. Renal tubular disease is the most frequent cause of renal failure. It is present in more than 55% of renal failure cases and in 75% of those requiring dialysis. Rapid reduction of free light chain levels in the blood is necessary in order to recover renal function. One coadjuvant measure in treating the disease is reducing light chain levels with plasmapheresis, but its efficacy has not yet been clearly proven. Our proposal was therefore to use extended haemodialysis sessions with high cut-off dialysers (HCO-HD), obtaining a recovery rate of more than 60%. We present the progress of 6 patients with myeloma and acute renal failure who were treated with HCO-HD and the complications associated with using this type of haemodialysis. Then, we review the pros and cons of this technique.
Method: Six patients diagnosed with MM and ARF requiring dialysis and with serum free light chain levels above 500 mg/l were treated with 8-hour haemodialysis sessions with an HCO-HD filter. Before and after each session, serum free light chain levels were measured by nephelometry; other parameters were recorded as well. At the same time, patients underwent chemotherapy according to protocols.
Results: The symptom onset times of the 3 men and 3 women diagnosed with MM and ARF were highly variable, from 7 days to more than 1 year. We performed 90 extended sessions with HCO-HD filters, and each patient underwent between 6 and 40 sessions. Free light chain levels decreased by a mean of 65% between treatment onset and completion, except in one patient who experienced a 12.6% reduction. The mean percentage of reduction of light chain levels per session was 54.98% ± 17.27%. A complication occurred during 28% of the sessions. Of these complications, 48% were due to system coagulation. There were no major changes in pre-dialysis albumin, calcium, phosphorous or magnesium levels, although lower values that were not clinically relevant were recorded in one case. Renal function was recovered in 3 patients, they are alive and dialysis-free. In biopsied cases that recovered renal function, the specimen showed tubular nephropathy only. Those patients who took longer to be diagnosed did not recover their renal function, and when biopsied, they were diagnosed with renal tubular disease and light chain deposition disease.
Conclusion: We found extended haemodialysis with HCO-HD filters to be a reasonable alternative in ARF caused by renal tubular disease, and achieved a recovery rate of 50% in our cases. Function recovery was influenced by the elapsed time between symptom onset and myeloma diagnosis, histological findings, promptness of starting chemotherapy, response to chemotherapy, and effectiveness of light chain extraction. In any case, further studies are needed to examine new chemotherapy agents and new direct free light chain removal techniques.
Comment in
-
The value of serum free light chain assay in patients with monoclonal gammopathies and renal failure.Nefrologia. 2012;32(1):15-9. doi: 10.3265/Nefrologia.pre2011.Nov.11098. Nefrologia. 2012. PMID: 22294000 English, Spanish. No abstract available.
-
Comment on "Haemodialysis using high cut-off dialysers for treating acute renal failure in multiple myeloma".Nefrologia. 2012 May 14;32(3):396. doi: 10.3265/Nefrologia.pre2012.Feb.11392. Nefrologia. 2012. PMID: 22592425 No abstract available.
Similar articles
-
Immunoglobulin free light chain levels and recovery from myeloma kidney on treatment with chemotherapy and high cut-off haemodialysis.Nephrol Dial Transplant. 2012 Oct;27(10):3823-8. doi: 10.1093/ndt/gfr773. Epub 2012 Jan 23. Nephrol Dial Transplant. 2012. PMID: 22273664
-
Treatment by long haemodialysis sessions with high cut-off filters in myeloma cast nephropathy: our experience.Nefrologia. 2013;33(4):515-23. doi: 10.3265/Nefrologia.pre2013.Feb.11932. Nefrologia. 2013. PMID: 23897183 English, Spanish.
-
Thirteen treated of acute renal failure secondary to multiple myeloma with high cut off filters.Nefrologia. 2016 Jul-Aug;36(4):418-26. doi: 10.1016/j.nefro.2016.03.011. Epub 2016 May 31. Nefrologia. 2016. PMID: 27255910 English, Spanish.
-
Management options for cast nephropathy in multiple myeloma.Curr Opin Nephrol Hypertens. 2010 Nov;19(6):550-5. doi: 10.1097/MNH.0b013e32833ef72c. Curr Opin Nephrol Hypertens. 2010. PMID: 20827195 Review.
-
Current approach to diagnosis and management of acute renal failure in myeloma patients.Adv Chronic Kidney Dis. 2012 Sep;19(5):297-302. doi: 10.1053/j.ackd.2012.06.001. Adv Chronic Kidney Dis. 2012. PMID: 22920640 Review.
Cited by
-
Current Trends of Renal Impairment in Multiple Myeloma.Kidney Dis (Basel). 2016 Mar;1(4):241-57. doi: 10.1159/000442511. Epub 2016 Feb 3. Kidney Dis (Basel). 2016. PMID: 27536684 Free PMC article. Review.
-
Hemodiafiltration with ultrafiltrate regeneration reduces free light chains without albumin loss in multiple myeloma patients.BMC Nephrol. 2020 Jun 15;21(1):227. doi: 10.1186/s12882-020-01885-8. BMC Nephrol. 2020. PMID: 32539688 Free PMC article.
-
The role of technological progress vs. accidental discoveries and clinical experience.Med Sci Monit. 2013 Nov 13;19:984-92. doi: 10.12659/MSM.889710. Med Sci Monit. 2013. PMID: 24226207 Free PMC article. Review.
-
Middle molecule clearance with high cut-off dialyzer versus high-flux dialyzer using continuous veno-venous hemodialysis with regional citrate anticoagulation: A prospective randomized controlled trial.PLoS One. 2019 Apr 26;14(4):e0215823. doi: 10.1371/journal.pone.0215823. eCollection 2019. PLoS One. 2019. PMID: 31026303 Free PMC article. Clinical Trial.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous